Zelixir Bio: Pioneering Biological Manufacturing and Empowering a Green Future

Zelixir

1. Bio-computing Services:

FastZfold (Ultra-fast Protein Structure Modeling):

By designing the fastMSA ultra-fast homologous sequence matching method, similar sequences can be quickly found in massive datasets, saving significant computational resources for sequence alignment and allowing FastZfold technology's performance to lead globally in structural modeling.

ZPoint (High-Precision Protein Binding Site Prediction Service):

By deeply integrating advanced artificial intelligence technology, the binding sites of protein-ligand interactions (small molecules, other proteins, etc.) are predicted, providing crucial support for drug design and biological research.

zPoseScore (High-precision Conformation Prediction Tool):

It is the core application of Zelixir's virtual screening services, combined with the Zelixir HPC computing system, helping customers quickly identify potential drug candidates and accelerate the drug discovery process. Similarly, this technology also supports reverse virtual screening.

NYAN (Self-Coding Model Molecular Generation Business):

Advanced biocomputing services aim to use autoencoder models to generate compounds with expected bioactivity based on target characteristics set by clients, expand chemical space, and provide new candidates for drug development.

2. Design Services:

Enzyme Engineering Process Design and Optimization:

By leveraging a large amount of real-world data and advanced machine learning algorithms, Zelixir has developed an accurate enzyme property prediction system, significantly improving the efficiency of enzyme mutation design. The iteration cycle has been greatly shortened, effectively enhancing enzyme activity to meet customers' needs for enzyme discovery and enzyme optimization.

AI + Computational-Based Innovative Design of Drug Molecules:

By accurately predicting various molecular properties, such as bioactivity, pharmacokinetic characteristics, and safety, the most promising drug candidate molecules can be screened out, thereby improving the success rate and efficiency of drug development. This technology is applicable to scenarios such as De novo inhibitor design and hit compound discovery, offering advantages of high precision, the ability to screen drugs for unknown targets, and high throughput, providing reliable support for drug development.

3. Joint Custom Development of Bio-based Raw Materials:

By leveraging keen front-end market and user insights, combined with Zelixir's self-developed "IT+BT+VT" 3T closed-loop, we accelerate the industrialization and commercialization of raw materials and products. Our development costs and industry cycles are 50% lower than the industry average.

Cooperation Model: Conduct in-depth cooperation with industry partners to achieve the transformation of scientific research and technological achievements in the fields of biopharmaceuticals, food health, beauty care, and green agriculture, realizing the joint development, joint production, and joint sales of bio-based raw materials.